No Prescription |
 |
 | ||
|
Activelle Generic Estradiol Norethindrone |
|
| ||
No Prescription » Prescription Drugs 1 » Activelle Generic Estradiol Norethindrone For the Treatment of moderate to severe vasomotor symptoms occurring in naturally orsurgically induced estrogen deficiency states.Treatment of vulvar or vaginal atrophy associated with menopause.ActivelleĞ is recommended only in women with intact uteri since the regimen includes a progestogen to prevent endometrial hyperplasia. Buy Activelle Generic Estradiol Norethindrone and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Activelle Generic Estradiol Norethindrone: Product Type: Prescription Drugs 1 Activelle ( Generic Estradiol & Norethindrone ) Activelle (Generic Estradiol & Norethindrone) Generic Estradiol & Norethindrone 1mg/0.5mg 84 Tablets 1mg/0.5mg 168 Tablets 1mg/0.5mg 28 Tablets Generic Estradiol & Norethindrone Activelle
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
